Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
MARKET INSIGHTS
The global Single Use Technologies for Biopharmaceuticals market was valued at USD 8.86 billion in 2024 and is projected to reach USD 20.09 billion by 2031, exhibiting a CAGR of 12.4% during the forecast period.
Single-use technologies (SUT) refer to disposable bioprocessing equipment and components designed for one-time use in biopharmaceutical manufacturing. These include single-use bioreactors, membrane adsorbers, media bags, and bioprocess containers, which eliminate the need for cleaning and sterilization between batches. The technology offers advantages such as reduced contamination risks, lower capital expenditure, and increased operational flexibility compared to traditional stainless-steel systems.
The market growth is driven by the rising demand for biologics, which accounted for USD 381 billion of the global pharmaceutical market in 2022. While traditional pharmaceutical manufacturing faces challenges with stringent regulations and high costs, SUT provides a cost-effective solution for both contract manufacturing organizations (CMOs) and biopharmaceutical manufacturers. Recent developments include Thermo Fisher's 2023 acquisition of a leading SUT components manufacturer to expand its bioprocessing portfolio, reflecting the industry's strategic focus on these technologies.
Cost Efficiency and Reduced Contamination Risk
The adoption of single-use technologies in biopharmaceuticals is driven by their significant cost savings compared to traditional stainless-steel systems, reducing cleaning and sterilization expenses by approximately 30-40%. These systems also minimize cross-contamination risks in multi-product facilities.
Accelerated Drug Development Timelines
Single-use technologies enable faster facility setup and changeover between production batches, cutting validation time by up to 50% compared to traditional systems. This agility is critical for responding to pandemic demands and personalized medicine production.
The global single-use bioprocessing market is projected to grow at a CAGR of 14.2% from 2023 to 2029, reaching $24.8 billion
Regulatory support for single-use systems has increased, with agencies like the FDA recognizing their quality-by-design advantages and reduced validation burden through standardized, pre-sterilized components.
MARKET CHALLENGES
Extractables and Leachables Concerns
Characterization of extractables and leachables remains a technical hurdle, particularly for sensitive biologics. Current analytical methods can detect compounds at ppm levels, but thresholds continue to tighten for high-risk therapeutics.
Other Challenges
Supply Chain Vulnerabilities
Dependence on polymer suppliers creates bottlenecks, with single-use bag lead times extending to 16-20 weeks during peak demand periods.
Scalability Limitations
While suitable for clinical-scale production, single-use systems face technical constraints in commercial-scale manufacturing of high-volume biologics, particularly for mAbs exceeding 5,000L scales.
Environmental and Sustainability Pressures
The disposal of single-use plastics generates approximately 350 tons of waste per year for mid-sized biopharma companies. Increasing regulatory scrutiny on plastic waste and emerging EPR regulations may impact adoption rates.
High Initial Adoption Costs
Transitioning to single-use requires substantial capital expenditure for facility redesign and workforce retraining, with complete conversion costs ranging $15-25 million for typical biologics facilities.
Modular and Mobile Biomanufacturing
The integration of single-use technologies with modular cleanroom designs enables rapid deployment of manufacturing capacity, with some vendors offering turn-key solutions that reduce facility construction time by 60%.
Emerging Biosimilar and Cell Therapy Markets
Single-use systems are becoming the default platform for cell and gene therapies, accounting for 80% of new therapy manufacturing installations due to their closed-system advantages and reduced contamination risks.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Single-use Bioreactors dominate due to their widespread adoption in biopharmaceutical production, offering operational flexibility and reduced cross-contamination risks. The market shows strong preference for these systems as they significantly reduce capital investment in stainless steel infrastructure while maintaining comparable production yields for biologics. |
| By Application |
|
Biopharmaceutical Manufacturers represent the largest application segment due to the growing biologics pipeline and need for flexible manufacturing solutions. These manufacturers value the rapid deployment capabilities of single-use systems that support multi-product facilities. The technology enables faster turnaround times between production campaigns, which is critical for meeting biologics demand. |
| By End User |
|
Large-scale Biopharma Companies lead adoption as they increasingly integrate single-use technologies into commercial-scale manufacturing. These established players leverage the technology's benefits for both existing product portfolios and new molecule development. The technology aligns well with current Good Manufacturing Practice requirements while offering capital expenditure advantages over traditional stainless steel systems. |
| By Technology Maturity |
|
Established Technologies maintain market dominance as biopharma firms prefer proven solutions with regulatory track records. Market leaders continue investing in product enhancements like higher capacity single-use bioreactors while maintaining compatibility with existing unit operations. The market shows cautious optimism toward novel single-use solutions that require additional validation. |
| By Integration Level |
|
Modular Systems are gaining significant traction as they offer the perfect balance between flexibility and process control. These systems allow pharmaceutical companies to build customized production trains while maintaining the benefits of single-use technology. The approach particularly benefits facilities requiring multiple product manufacturing capabilities within the same physical space. |
Dominance of Major Players in Single-Use Bioprocessing Technologies
The single-use technologies for biopharmaceuticals market is led by multinational corporations with extensive product portfolios and global distribution networks. Thermo Fisher Scientific currently holds a dominant position through its acquisition of Pall Corporation and subsequent integration of single-use technologies. Sartorius Stedim Biotech has emerged as another key player, focusing specifically on single-use bioreactors and bioprocess containers, capturing significant market share in Europe and Asia.
Several specialized manufacturers are gaining traction in niche segments. EMD Millipore (Merck KGaA) maintains strong positions in membrane adsorbers and filtration systems, while Danaher Corporation leverages its Cytiva brand (formerly GE Healthcare Life Sciences) in media bags and disposable mixing systems. Emerging players like Meissner Filtration Products and Entegris are making strategic advances in single-use assemblies for smaller biotech firms.
List of Key Single-Use Technologies for Biopharmaceuticals Companies ProfiledThermo Fisher Scientific Inc.
Merck KGaA (EMD Millipore)
Danaher Corporation (Cytiva)
Meissner Filtration Products
Corning Incorporated
Parker Hannifin Corporation
Saint-Gobain
Repligen Corporation
Cesco Bioengineering
Solida Biotech
Distek Inc.
The global Single Use Technologies for Biopharmaceuticals market was valued at million in 2024 and is projected to reach US$ million by 2031, growing at a CAGR of % during the forecast period. This growth is driven by increasing demand for flexible and cost-effective bioprocessing solutions, particularly for biologics production which is expected to reach $381 billion in 2022. The technology eliminates cleaning validation requirements and reduces cross-contamination risks in biopharmaceutical manufacturing.
Other TrendsExpansion in Contract Manufacturing
Contract Manufacturing Organizations are adopting single-use technologies at a rapid pace, accounting for significant market share. These systems enable faster changeovers between different drug production campaigns, reducing downtime and improving manufacturing efficiency. The flexibility offered by single-use systems aligns perfectly with the business model of CMOs serving multiple clients.
Technological Advancements in BioprocessingRecent developments include improved single-use bioreactors with enhanced scalability up to 2,000 liters and advanced sensor technologies for better process monitoring. Leading companies like EMD Millipore, GE Healthcare, and Sartorius Stedim Biotech are investing heavily in R&D to expand their single-use product portfolios. Membrane adsorbers are emerging as a key segment, offering efficient purification solutions for biologic production.
Regional Market Growth PatternsNorth America currently leads in single-use technology adoption, followed by Europe, with Asia showing the fastest growth rate. This reflects the expansion of biopharmaceutical manufacturing capabilities in emerging markets like China and India. The market in Southeast Asia is expected to grow at above-average rates due to increasing investments in biologics manufacturing infrastructure.
Regional Analysis: Single Use Technologies for Biopharmaceuticals MarketEurope
Europe represents the second-largest market for single-use biopharmaceutical technologies, with Germany and Switzerland as key contributors. The region shows strong adoption in vaccine production and monoclonal antibody manufacturing. EMA's updated guidelines provide clarity on single-use system implementation, particularly regarding extractables and leachables testing. Northern European countries lead in adopting single-use technologies for advanced therapy medicinal products (ATMPs). Challenges include plastic waste regulations impacting disposal of disposable components, driving innovation in sustainable materials for single-use systems.
Asia-Pacific
Asia-Pacific emerges as the fastest growing market, with China and India showing robust expansion. Increasing biologics production and government support for biopharmaceutical manufacturing drive adoption. Singapore serves as regional hub with advanced bioprocessing facilities implementing disposable technologies. South Korea and Japan focus on single-use systems for biosimilars production. Market growth is tempered by preference for stainless steel in established facilities and need for localized technical support for single-use system implementation.
South America
Brazil leads South America's adoption of single-use technologies in vaccine and insulin production. Regional market remains relatively small but shows gradual growth with increasing biopharmaceutical manufacturing capabilities. Challenges include higher import costs for disposable components and limited local manufacturing of single-use systems. Argentina shows potential in single-use technology adoption for veterinary biologics production.
Middle East & Africa
Middle East demonstrates growing interest in single-use technologies through investments in biopharmaceutical manufacturing infrastructure. UAE and Saudi Arabia lead regional adoption, particularly for vaccine production. Africa shows limited but emerging use in localized vaccine manufacturing initiatives, with South Africa at the forefront. Market expansion is constrained by high costs and need for cold chain logistics for pre-sterilized single-use components.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global single use technologies for biopharmaceuticals market was valued at USD 8.86 billion in 2024 and is expected to reach USD 20.09 billion by 2031.
-> Key players include EMD Millipore, GE Healthcare, Pall Corp, Sartorius Stedim Biotech, and Thermo Fisher.
-> Key growth drivers include rising demand for biologics, lower capital expenditure requirements, and increased operational flexibility.
-> North America currently holds the largest market share, while Asia-Pacific is expected to show the highest growth.
-> Emerging trends include expansion of bioprocessing portfolios through strategic acquisitions and increased adoption in contract manufacturing organizations.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates